June 12, 2020 10:55 AM EDT

Sanofi and Regeneron outline Dupixent plans; Industry lobbying brings £30 million for UK's Biomedical Catalyst

→ Sanofi and Regeneron outlined the future for their blockbuster IL-4/IL-13 blocker Dupixent in an investor call and press release …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi and Re­gen­eron out­line Dupix­ent plans; In­dus­try lob­by­ing brings £30 mil­lion for UK's Bio­med­ical Cat­a­lyst